PPF87 Integrating palliative care outcomes collaboration with interstitial lung disease palliative care needs assessment: proof of concept

Read full text Summarise with VIRAT
Authors: Wen Yan Low, Frances O’Mahony, Lindsay Brown, Leisi Garcia, Sarah Mabelson, Eoin Tiernan, Cormac McCarthy
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Interstitial lung disease (ILD) is a heterogenous group of irreversible life-limiting diseases with high symptom burden. Distinct to the clinician- and patient-reported palliative needs assessment tools – Needs Assessment Tool: Progressive Disease - ILD and King’s Brief ILD questionnaire, we sought to investigate the utility of PCOC as another objective measure to identify critical disease timepoints to facilitate timely referral from specialist ILD clinics to Palliative Care (PC). Methodology We designed a tool which collects patient demographics, albumin, spirometry data, GAP index for Idiopathic Pulmonary Fibrosis (IPF) mortality prediction, prognostic indicators for ILD according to European Respiratory Society guidelines, Australian-modified Karnofsky Performance Scale (AKPS), and Edmonton Symptom Assessment Scale (ESAS). The pilot project ran from 15/05/2025 to 10/07/2025. Clinicians completed the tool with all patients in clinic. Data was analysed in Excel and statistical significance measured with two-tailed Mann-Whitney U Test. Results Of the 77 patients, 55% patients are female with average age 62.4±15.9, weight 78.5±21.9kg, BMI 28.7±6.2, Albumin 36.6±4.6g/dL, median AKPS 80 and GAP 3. Main diagnoses are Sarcoidosis (29%), connective tissue disease related ILD (23%), Fibrotic hypersensitivity pneumonitis (13%), and IPF (13%). Patients on ambulatory oxygen have ~15% lower FVC and DLCO, albumin 33.9±6.3g/dL and AKPS 70. They report more dyspnoea, fatigue and wellbeing loss (Median ESAS on oxygen=5,6,5; without=3,2.5,1). This worsens when prescription is recently increased (ESAS=8,5,8) or when they need oxygen at rest (ESAS=8,5,10). GAP≥6 (7%) with extremely reduced lung function has lower median albumin 29.2±7.3g/dL and AKPS 60, and is correlated with higher scores in fatigue, dyspnoea, appetite and wellbeing loss (ESAS overall=3,3,1,1; GAP≥6=5,8,5,7). Patients reporting any unintentional weight loss have >10% lower FVC and DLCO. Radiological progression and antifibrotic use did not correlate with worse spirometry or symptoms. Conclusion ESAS and AKPS provides useful objective measurements to support established prognostic indicators to guide decision to refer to PC.

Fields of Study & Subjects

Palliative Care and End-of-Life Issues Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Palliative and Oncologic Care

Publication details

Journal / source
BMJ Supportive & Palliative Care
Pages
A77–A77
Publication date
25 March 2026
Language
EN